AptarGroup (ATR) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.42
- Estimate
- $1.35
- Surprise
- +4.8%
- Score at report (before → after)
- 5.5 → 5.6/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
AptarGroup (ATR) beat the $1.35 estimate with adjusted EPS of $1.42 — a clear 4.8% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.5/10) to Hold at 5.6/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ATR Sell at 5.2/10.
4 of the last 4 quarters beat the estimate; this quarter's +4.8% surprise compares with a +3.4% four-quarter average. Next scheduled report: 2027-02-04.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Supplier: single-source resins and rubber components
- Analyst target reached - limited upside remaining
- Near 52-week high (3.1% away)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $142.31
- Price target
- $142.57
- Stop
- $135.19
- Upside to target
- +0.2%
- Reward-to-risk
- 0.0:1
At 26.0× trailing and 23.3× forward earnings, consensus estimates imply little change in earnings power.
Risk check: RSI 87 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-03 — shown for context, not personalized investment advice.
ATR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $9.12B
- P/E (fwd)
- 23.3
- P/E (ttm)
- 26.0
- 52-week range
- $108.29–$146.91
- Off 52-week high
- 3.1%
- RSI (14)
- 87
- Volume vs avg
- 1.23×
- Score today
- 5.2/10